WATER II Trial (Aquablation)

AbstractPurpose of ReviewThis review discusses the role of aquablation therapy for the treatment of benign prostatic hyperplasia in those with prostate volumes between 80 and 150  mL (WATER II trial).Recent FindingsAquablation therapy reduced International Prostate Symptoms Scores, improved urinary flow rate, and preserved ejaculatory function in the majority of sexually active patients. Other advantages include faster operative times and a shorter learning curve. Adverse events were low and predominantly centered around bleeding risk.SummaryAquablation therapy is effective and safe in the surgical management of large prostates thereby offering alternatives to surgeons and patients alike.
Source: Current Bladder Dysfunction Reports - Category: Urology & Nephrology Source Type: research